Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Read . . . → Read More: Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis Similar Articles: Company Update (NYSE:MRK): Merck Announces Third-Quarter 2014 Dividend Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C Company Update (NYSE:MRK): Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29